Clinicaltrial Investment Portfolios

Novartis Announces Statistically Significant Reduction in Proteinuria with Fabhalta® in Phase III C3G Study May 26, 2024
Companies
AIM ImmunoTech Commences Key Study for Pancreatic Cancer Treatment in Partnership with AstraZeneca Feb 15, 2024
Pharmaceuticals
BioNTech and DualityBio Start Key Phase 3 Trial for Metastatic Breast Cancer Treatment Jan 23, 2024
Healthcare
SciSparc Embarks on a Phase IIb Trial of THC-Based Treatment for Tourette Syndrome Nov 11, 2023